Skip to main content
SpringerLink
Log in

Distribution of CCND1 A870G Polymorphism in Patients with Advanced Uterine Cervical Carcinoma

  • Published:
Pathology & Oncology Research

Abstract

We examined the distribution of the CCND1 A870G (rs9344) polymorphic variant in patients with cervical cancer (n = 129) and healthy individuals (n = 288) in a sample of a Polish cohort. We showed that patients with advanced cervical cancer bearing the CCND1 A/A and A/G genotypes displayed a 1.811-fold increased risk of cervical cancer (95% CI = 1.150–2.852, p = 0.0098). We also found a significantly higher frequency of the CCND1 870A allele in patients with cancer than in controls, p = 0.0116. Our investigation confirmed that the CCND1 870A gene variant may be a genetic risk factor in the incidence of advanced cervical cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. Parkin DM, Bray F (2006) Chapter 2: the burden of HPV-related cancers. Vaccine 24(S3):11–25

    Article  Google Scholar 

  3. Muñoz N, Bosch FX, de Sanjosé S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527

    Article  PubMed  Google Scholar 

  4. Baseman JG, Koutsky LA (2005) The epidemiology of human papillomavirus infections. J Clin Virol 32(Suppl 1):S16–24

    Article  PubMed  Google Scholar 

  5. Magnusson PK, Sparen P, Gyllensten UB (1999) Genetic link to cervical tumours. Nature 400:29–30

    Article  PubMed  CAS  Google Scholar 

  6. Hemminki K, Dong C, Vaittinen P (1999) Familial risks in cervical cancer: is there a hereditary component? Int J Cancer 82:775–781

    Article  PubMed  CAS  Google Scholar 

  7. Hemminki K, Chen B (2006) Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol BiomarkersPrev 15:1413–1414

    Article  Google Scholar 

  8. Kim JK, Diehl JA (2009) Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 220:292–296

    Article  PubMed  CAS  Google Scholar 

  9. Hall M, Peters G (1996) Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68:67–108

    Article  PubMed  CAS  Google Scholar 

  10. Wang L, Habuchi T, Mitsumori K et al (2003) Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 103:116–120

    Article  PubMed  CAS  Google Scholar 

  11. Onay UV, Aaltonen K, Briollais L et al (2008) Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 8:6

    Article  PubMed  Google Scholar 

  12. Le Marchand L, Seifried A, Lum-Jones A et al (2003) Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA 290:2843–2848

    Article  PubMed  Google Scholar 

  13. Rydzanicz M, Golusinski P, Mielcarek-Kuchta D et al (2006) Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx. Eur Arch Otorhinolaryngol 263:43–48

    Article  PubMed  Google Scholar 

  14. Izzo JG, Malhotra U, Wu TT et al (2005) Impact of cyclin D1 A870G polymorphism in esophageal adenocarcinoma tumorigenesis. Semin Oncol 32:S11–5

    Article  PubMed  CAS  Google Scholar 

  15. Hou X, Wang S, Zhou Y et al (2005) Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Int J Hematol 82:206–209

    Article  PubMed  CAS  Google Scholar 

  16. Castro FA, Haimila K, Sareneva I et al (2009) Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population–a candidate gene approach. Int J Cancer 125:1851–1858

    Article  PubMed  CAS  Google Scholar 

  17. Thakur N, Hussain S, Kohaar I et al (2009) Genetic variant of CCND1: association with HPV-mediated cervical cancer in Indian population. Biomarkers 14:219–225

    Article  PubMed  CAS  Google Scholar 

  18. Satinder K, Chander SR, Pushpinder K et al (2008) Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population. Mol Cell Biochem 315:151–157

    Article  PubMed  CAS  Google Scholar 

  19. Betticher DC, Thatcher N, Altermatt HJ et al (1995) Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11:1005–11011

    PubMed  CAS  Google Scholar 

  20. Lu F, Gladden AB, Diehl JA (2003) An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63:7056–7061

    PubMed  CAS  Google Scholar 

  21. Solomon DA, Wang Y, Fox SR et al (2003) Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 278:30339–30347

    Article  PubMed  CAS  Google Scholar 

  22. Jeon YT, Kim JW, Song JH et al (2005) Cyclin D1 G870A polymorphism and squamous cell carcinoma of the uterine cervix in Korean women. Cancer Lett 223:259–263

    Article  PubMed  CAS  Google Scholar 

  23. Catarino R, Matos A, Pinto D et al (2005) Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet 160:49–54

    Article  PubMed  CAS  Google Scholar 

  24. Martin CM, Astbury K, O'Leary JJ (2006) Molecular profiling of cervical neoplasia. Expert Rev Mol Diagn 6:217–229

    Article  PubMed  CAS  Google Scholar 

  25. Sherr CJ (1993) Mammalian G1 cyclins. Cell 73:1059–1065

    Article  PubMed  CAS  Google Scholar 

  26. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512

    Article  PubMed  CAS  Google Scholar 

  27. Jares P, Colomer D, Campo E (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 7:750–762

    Article  PubMed  CAS  Google Scholar 

  28. Jin M, Inoue S, Umemura T et al (2001) Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 34:207–218

    Article  PubMed  CAS  Google Scholar 

  29. Bartkova J, Lukas J, Muller H et al (1995) Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 55:949–956

    PubMed  CAS  Google Scholar 

  30. Bartkova J, Lukas J, Muller H et al (1994) Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57:353–361

    Article  PubMed  CAS  Google Scholar 

  31. Shamma A, Doki Y, Shiozaki H et al (2000) Cyclin D1 overexpression in esophageal dysplasia: a possible biomarker for carcinogenesis of esophageal squamous cell carcinoma. Int J Oncol 16:261–266

    PubMed  CAS  Google Scholar 

  32. Al Moustafa AE, Foulkes WD, Wong A et al (2004) Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. Oncogene 23:5252–5256

    Article  PubMed  CAS  Google Scholar 

  33. Wang L, Habuchi T, Takahashi T et al (2002) Carcinogenesis 23:257–264

    Article  PubMed  Google Scholar 

  34. Pabalan N, Bapat B, Sung L et al (2008) Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomarkers Prev 17:2773–2781

    Article  PubMed  CAS  Google Scholar 

  35. Huh K, Zhou X, Hayakawa H et al (2007) Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol 81:9737–9747

    Article  PubMed  CAS  Google Scholar 

  36. Huh KW, DeMasi J, Ogawa H et al (2005) Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc Natl Acad Sci U S A 102:11492–11497

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Supported by grant No 502-01-01124182-07474, Poznań University of Medical Sciences.

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Biology, Poznań University of Medical Sciences, 6 Święcickiego St., 60-781, Poznań, Poland

    Teresa Warchoł, Łukasz Kruszyna, Margarita Lianeri & Paweł P. Jagodziński

  2. Department of Radiotherapy and Gynecological Oncology, Greater Poland Cancer Centre, Poznań, Poland

    Andrzej Roszak

Authors
  1. Teresa Warchoł
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Łukasz Kruszyna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Margarita Lianeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrzej Roszak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paweł P. Jagodziński
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paweł P. Jagodziński.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Warchoł, T., Kruszyna, Ł., Lianeri, M. et al. Distribution of CCND1 A870G Polymorphism in Patients with Advanced Uterine Cervical Carcinoma. Pathol. Oncol. Res. 17, 133–137 (2011). https://doi.org/10.1007/s12253-010-9293-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-010-9293-3

Keywords

Search

Navigation